Shenzhen Edge Medical Co (Ticker: 2675 HK) is a Chinese medical equipment company specializing in advanced surgical robotics. The company, formally Shenzhen Edge Medical Co., Ltd., plans to list on the Hong Kong Stock Exchange on January 8, 2026. The offering consists of 27.72 million H-shares at a price of HKD 43.24 per share, aiming to raise HKD 1.20 billion (approximately USD 154 million). This implies a market capitalization of approximately HKD 16.77 billion (USD 2.15 billion).

The company intends to use the IPO proceeds for research and development (R&D), product capacity expansion, brand promotion, business development, working capital, and strategic acquisitions. Founded in 2017, Shenzhen Edge Medical designs and manufactures robot-assisted devices for minimally invasive surgery (MIS). Its portfolio includes the "Edge Multi-Port" and "Edge Single-Port" Endoscopic Surgical Robots, both of which are core products approved by China's NMPA and have received CE Marking in the EU. The company claims to be the first in China to receive registration approvals for multi-port, single-port, and natural orifice surgical robots. In 2024, it reportedly ranked first among domestic manufacturers in sales of multi-port units. The offering is sponsored by Morgan Stanley and GF Capital.